MAOB and Parkinson disease: A review by the American Academy of Neurology (AAN) in 2006 concluded that DAs, MAO-B inhibitors, and levodopa do not provide disease-modifying properties, reinforcing the emphasis on symptomatic management as the primary treatment goal for PD [7].